Educating Providers and Patients on Targeted Oral Therapies for HR+/HER2- Breast Cancer

Join us for this online, live talk show–style Webinar as expert faculty discuss the most recent data on oral therapies for patients with HR+/HER2− breast cancer, including the latest data for CDK4/6 and PI3K inhibitors in early and advanced disease.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


Welcome and Introduction

Application of CDK4/6 Inhibitors in HR+/HER2-
Discussion of biomarker testing, implications for treatment recommendations, and current data and ongoing clinical trials on use of CDK4/6 inhibitors in HR+/HER2- EBC. 

Selection and Sequence of Oral Targeted Therapy for HR+/HER2- ABC
Exploring the use and selection of CDK4/6 and PI3K inhibitors with endocrine therapy for advanced disease, including current efficacy, safety, and administration considerations. 

Strategies for Promoting Adherence to CDK4/6 and PI3K Inhibitors
Understanding the importance of coordination of care and communication among the multidisciplinary team and patients for optimal treatment adherence. 

Patient Education and Communication Strategies to Optimize CDK4/6 and PI3K Inhibitor AE Management
Discussion of communication strategies and key considerations for educating patients on AEs associated with CDK4/6 and PI3K inhibitors.

Final Thoughts


Date / Time
Event Details


Program Director
Joyce O'Shaughnessy, MD

Matthew Goetz, MD

Professor of Oncology and Pharmacology
Director, Mayo Breast Cancer SPORE
Co-PI, Women's Cancer Program
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Sara Hurvitz, MD

Associate Professor of Medicine
Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Target Audience
This educational program is intended for oncologists, advanced practice clinicians, oncology nurses, navigators, pharmacists, and other supportive services who care for patients with HR+/HER2- EBC and ABC.

Learning Objectives

  • Address gaps in patient-provider knowledge and perceptions about targeted oral therapies for HR+/HER2- EBC and ABC
  • Foster collaborative discussions between patients/caregivers and providers on guidelines and recent clinical evidence to guide personalized treatment planning for HR+/HER2- EBC and ABC
  • Recognize and manage adverse events associated with approved CDK4/6 and PI3K inhibitors
  • Implement resources to engage patients in shared decision-making about treatment for HR+/HER2- EBC and ABC with targeted oral therapies


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. UAN: JA4008176-0000-21-003-L01-P

Type of Activity: Knowledge

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.